Phase I Study of Nimotuzumab in Solid Tumours

Advanced and/or Metastatic Solid Tumours Clinical Trial

Official title:

A Phase I Study of TheraCIM-hR3 (YMB1000) in Patients With Solid Tumours

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00369252
• Other study ID #: YMB1000-007
• Status: Completed
• Phase: Phase 1
• First received: August 25, 2006
• Last updated: February 27, 2007
• Start date: June 2005

Study information

• Verified date: February 2007
• Source: YM BioSciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health CanadaCanada: Ethics Review Committee
• Study type: Interventional

Clinical Trial Summary

This is a phase I trial of nimotuzumab that will be conducted in patients with advanced incurable solid tumors. This is a dose-seeking study to determine the maximum tolerated and recommended phase II doses of nimotuzumab that can be safely given to patients with advanced and/or metastatic solid tumors.

Description:

This is an open-label, dose-escalating, phase I trial of nimotuzumab in patients with advanced incurable solid tumors. The objective of this study is to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of nimotuzumab that can be given in a weekly schedule in patients with advanced and/or metastatic solid tumor cancer. This study will also examine the safety, pharmacodynamics and preliminary efficacy of nimotuzumab in this patient population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Advanced and/or metastatic solid tumors, refractory to standard curative therapy, or for which no curative therapy exists.

• Clinically or radiologically documented disease. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan.

• Archival tumor specimens evaluable for expression of the EGFR (but EGFR positivity is not a requirement for study entry).

• Patients must have tumor lesions accessible for biopsy for correlative studies. In cases where there are medical contraindications to tumor biopsies, exceptions may be made upon discussion with the Principal Investigators.

• Age > 18 years.

• ECOG performance status of 0,1,2.

• Previous therapy: Previous chemotherapy, hormonal therapy, radiation and/or surgery is permitted with certain restrictions as outlined in the protocol.

• Hematology and chemistry lab results within specifications outlined in the protocol.

• Willingness to give written informed consent.

• Patients must be accessible for treatment and follow-up.

• Protocol treatment is to begin within 2 working days of patient registration.

Exclusion Criteria:

• Pregnant or lactating women. Both men and women enrolled on study should be using adequate birth control measures throughout the course of the study.

• History of second malignancy who have a disease-free interval of less than two years (except cervical cancer in situ or nonmelanomatous skin cancer).

• Untreated brain or meningeal metastases. Patients with treated and stable brain metastases are eligible providing that they have radiologic evidence of disease stabilisation of at least 3 months duration and are asymptomatic.

• Untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction.

• Active or uncontrolled infections, or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol.

• Prior therapy with EGFR targeting therapies, including monoclonal antibodies or small molecule tyrosine kinase inhibitors.

• Allergy to the antibody.

• Concurrent treatment with other experimental drugs or anti-cancer therapy.

• Inability or unwillingness to give written, informed consent prior to study participation.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Advanced and/or Metastatic Solid Tumours

Intervention

Drug:
• Nimotuzumab (TheraCIM h-R3)

Locations

Country	Name	City	State
Canada	Princess Margaret Hospital	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
YM BioSciences	CIMYM BioSciences

Country where clinical trial is conducted

Canada,